报价延迟最少15分钟:2025/12/26 20:05 EST
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
49.84 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
1.63/7.60
|
|
企业价值
2.36B
|
| 资产负债 |
|
每股账面净值
8.69
|
| 现金流量 |
|
现金流量率
0.15
|
| 损益表 |
|
收益
631.45M
|
|
每股收益
17.29
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比较之报价最少15分钟延迟
|
业务概览
|
|||
| Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Jornay, Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic. |
